<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20130701122518+02'00'</creation_date><modification_date>D:20130701122518+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_w_dec_20.pdf</pdf_file></head><body><section><header>european commission bruxelles, 1.7.2013 c(2013)4233 (final)</header></section><section><header>commission implementing decision of 1.7.2013 
 amending the marketing authorisation granted by decision c(2004)3160 for “ariclaim -
 duloxetine hydrochloride”, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>commission implementing decision of 1.7.2013 
 amending the marketing authorisation granted by decision c(2004)3160 for 
 “ariclaim - duloxetine hydrochloride”, a medicinal product for human use</header><p>(text with eea relevance) (only the dutch text is authentic) 
 the european commission, 
 having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 2, and in particular article 20(7)(a) thereof, 
 having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by eli lilly nederland b.v. in accordance with regulation (ec) 
 no 1234/2008. 
 having regard to the opinion of the european medicines agency, formulated on 30 may 
 2013 by the committee for medicinal products for human use, 
 whereas: 
 (1)</p><p>the european medicines agency&apos;s opinion is favourable to the variation of the 
 terms of the decision granting the marketing authorisation as submitted by the 
 marketing authorisation holder. 
 (2)</p><p>the marketing authorisation should be updated and decision c(2004)3160 of 11 
 august 2004 should therefore be amended accordingly. the community register 
 of medicinal products should also be updated. 
 (3)</p><p>for the sake of clarity and transparency, it is appropriate, following the 
 amendment of part or parts of the annexes, to provide for a consolidated version 
 thereof. the annexes to decision c(2004)3160 should therefore be replaced.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 334, 12.12.2008, p. 7.</p><p> has adopted this decision: article 1 decision c(2004)3160 is amended as follows: 1) annex i is replaced by the text set out in annex i to this decision;</p><p>2) annex ii is replaced by the text set out in annex ii to this decision;</p><p>3) annex iii is replaced by the text set out in annex iii to this decision. 
 article 2 this decision is addressed to eli lilly nederland b.v., grootslag 1-5, nl-3991 ra houten, nederland. 
 done at brussels, 1.7.2013.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>